This is the beginning has raised funds b in $ 29 million in serion to scale Home Health Platform And use AI-designed antibodies to unlock new tests at home.
When the company launches its first fertility monitor in 2021, its goal is to make quantitative fertility hormone testing possible at home.
While standard at-home ovulation tests that track estrogen and luteinizing hormone (LH) are more fertile, they don’t measure the hormone that signals ovulation, which is your progesterone metabolite. Inito allows women to measure estrogen, Lh, progesterone (PDG), and FSH in the test strip. Inito’s AI model interprets these levels to reveal fertility hormile patterns, track fertile days, and confirm ovulation.
Fast forward to today, the startup has become a popular choice for women looking to track their hormone levels, with more than 30 million hormone data points as of 2021.
The startup is now doubling down on its belief that health should start at home, and is working to expand from a fertility tracker to a broader health tracker and diagnostic platform.
Inito is using the new funding to invest in and develop AI-engineered antibodies, which it says will enable the development of new tests and improve the accuracy of existing ones.
For context, when you take a test in the lab or at home, the antibody is the one that binds to the target molecule (like estrogen or testosterone) to generate a signal. Traditional antibodies are grown inside animals and then cut manually in a lab, which can be a slow and expensive process. Conventional antibodies also lack the sensitivity to make tests at home for many biokers.
TechCrunch events
San Francisco
I’m fat
October 13-15, 2026
Inito says AI designed antibodies are a game changer. Instead of “raising” antibodies in animals, it can be treated almost like software.
“We predict how proteins liper in 3D, design millions of variants, and use millions of variants, and explain one in the laboratory,” said Inito Co-founder and CTO Varun A Venkates in an email. “It produces antibodies that are more sensitive, consistent, and stable than anything developed through traditional methods.”
For Inporo, this will unlock the next generation of at-home testing. Venkates said the company has been using this method in R&D and the wet lab is showing promising results.
“The real vision is bigger than adding new tests,” said Inito Co-founder and CEO Aayush Rai. “The endgame is to expand all diagnostics. If you want to know what’s going on at every stage of life, you need to be able to measure, or give information about your body from home, with class confidence.”
Inito wants to expand that vision beyond the “try to engage” platform. The reader and app will test power for pregnancy, menopause, and broader health monitoring.
“Our long-term room is beyond fertility,” says Rai. “We are building to a platform that can measure and interpret the spectrum of hormones that are full of health. Menopause, all powered by Antibodi Ai and imaging that prepares Inito.”
The company will use part of the funding to manufacture globally to meet growing demand across the United States and new international markets.
The latest round of funding in Investment Information and Fireside Proposals. The investment brings the total funding to around $45 million. The company previously raised $6 million in funding from Fireside Ventures and $9 million from Combinator Y, former Nurx CEO Varsha Rao, and a dozen doctors and family officials.